396
On 31 August 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 392. The active ingredient is human monoclonal antibody against inhibitory killer cell lg-like receptors for treatment of acute myeloid leukaemia.